Abstract: This invention relates to the extraction of psychoactive compounds from fungus for use in medicine. Raw fungus is dried and ground. The solvent used for extraction is methanol or a hydro-methanol mixture, an acidic hydro-methanol mixture, or an alkaline hydro-methanol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The methanol in the solvent is then completely evaporated and water added back, where necessary, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted. The standardized slurry may then be dried to result in a powdered extract with a precisely defined purity of psychoactive compounds.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: A solution of extracted psychoactive alkaloids is obtained from psychoactive organisms or an existing extract using a neutral or acidic solvent. Acid extraction of psychoactive compounds from psychoactive organisms results in the dephosphorylated form of psychoactive alkaloids. The solution is basified to deprotonate the alkaloids. It is then subjected to a liquid-liquid extraction with a water-immiscible solvent. The resulting psychoactive organic layer is then subjected to a second liquid-liquid extraction with weakly acidic water. The resulting psychoactive aqueous layer is then dried to form a powder with the psychoactive alkaloid in a conjugate salt form. The powder may be standardized to a desired concentration of psychoactive alkaloid by the addition of an excipient. Alternatively, the standardization may be carried out on the psychoactive aqueous phase. Obtaining the psychoactive alkaloid in the conjugate salt form reduces the amount of non-psychoactive components included in the final extract.

Abstract: A solution of extracted psychoactive alkaloids is obtained from psychoactive organisms or an existing extract using a neutral or acidic solvent. Acid extraction of psychoactive compounds from psychoactive organisms results in the dephosphorylated form of psychoactive alkaloids. The solution is basified to deprotonate the alkaloids. It is then subjected to a liquid-liquid extraction with a water-immiscible solvent. The resulting psychoactive organic layer is then subjected to a second liquid-liquid extraction with weakly acidic water. The resulting psychoactive aqueous layer is then dried to form a powder with the psychoactive alkaloid in a conjugate salt form. The powder may be standardized to a desired concentration of psychoactive alkaloid by the addition of an excipient. Alternatively, the standardization may be carried out on the psychoactive aqueous phase. Obtaining the psychoactive alkaloid in the conjugate salt form reduces the amount of non-psychoactive components included in the final extract.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: This invention relates to the extraction of psychoactive compounds from psychedelic organisms for use in medicine. Raw psychedelic organisms are dried and pulverized. The psychoactive compounds are extracted using a solvent to result in an extraction slurry. The extraction slurry is filtered and pH-adjusted if necessary. The filtrate is then standardized to provide, when dried, a known concentration of the psychoactive alkaloids that have been extracted. The solvent is then evaporated from the filtrate to form the extract. The extract may be mixed with water and spray dried. The standardization process is run before or after full or partial evaporation of the solvent. The result is a powdered extract with a precisely defined concentration of psychoactive compounds.

Abstract: A solution of extracted psychoactive alkaloids is obtained from psychoactive organisms or an existing extract using a neutral or acidic solvent. Acid extraction of psychoactive compounds from psychoactive organisms results in the dephosphorylated form of psychoactive alkaloids. The solution is basified to deprotonate the alkaloids. It is then subjected to a liquid-liquid extraction with a water-immiscible solvent. The resulting psychoactive organic layer is subjected to evaporation to remove the water-immiscible layer. The resulting residue is dissolved in anhydrous acetone. Anhydrous acetone acidified with a weak acid is added to the solution to cause precipitation of a conjugate salt of the psychoactive alkaloid. The precipitate is dried and standardized to a desired concentration of psychoactive alkaloid by the addition of an excipient. Obtaining the psychoactive alkaloid in the conjugate salt form reduces the amount of non-psychoactive components included in the final extract.

Abstract: A transdermal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transdermal psychoactive alkaloid composition also includes an alcohol carrier, a permeation enhancer, a thickener or gelling agent, and optional further excipients. A process for obtaining a transdermal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: This liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The vaporizble psychoactive alkaloid composition includes an alcohol or polyol carrier, fatty acid, fatty alcohol, optional antioxidant, optional flavorant, and optional further excipients. A process for obtaining a vaporizble psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

Abstract: This invention relates to the extraction of psychoactive compounds from fungus for use in medicine. Raw fungus is dried and ground. The solvent used for extraction is methanol or a hydro-methanol mixture, an acidic hydro-methanol mixture, or an alkaline hydro-methanol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The methanol in the solvent is then completely evaporated and water added back, where necessary, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted. The standardized slurry may then be dried to result in a powdered extract with a precisely defined purity of psychoactive compounds.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: A transdermal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transdermal psychoactive alkaloid composition also includes an alcohol carrier, a permeation enhancer, a thickener or gelling agent, and optional further excipients. A process for obtaining a transdermal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.

Abstract: Methods for extracting and recovering bioactive components from a biomass feedstock with pressurized aqueous solvent solutions comprising one or more organic solutes and/or one or more inorganic solutes. The methods comprise the steps of: (i) preparing a selected aqueous solvent solution for pressurizing; (ii) providing a flow of the prepared aqueous solvent solution to a plant biomass feedstock contained within a pressure-resistant temperature-controllable reactor vessel (iii) warming the flow of aqueous solvent solution and the contents of the reactor vessel to a selected temperature; (iv) pressurizing the flow of the aqueous solvent solution and the contents of the reactor vessel to a selected pressure; (v) controllably flowing the pressurized aqueous solvent solution through the reactor vessel while maintaining the contents of the reactor vessel at the selected pressure; and (vi) collecting a flow of the pressurized aqueous solvent solution egressing from the reactor vessel for a selected period of time.

Abstract: A transmucosal psychoactive alkaloid composition including a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The transmucosal psychoactive alkaloid composition also includes a mucoadhesive polymer, a carrier, and optional further excipients. The non-ingestive composition may be taken orally through the mucosa. A process for obtaining an oral transmucosal psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid and standardizing to a specific concentration by adding measured quantities of excipients.

Abstract: This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.

Abstract: This invention relates to the extraction of psychoactive compounds from psilocybin fungus for use in medicine. Raw psilocybin fungus is dried and ground. The solvent used for extraction is a lower aliphatic alcohol, water, a hydro-alcohol mixture, an acidic hydro-alcohol mixture, or an alkaline hydro-alcohol mixture. The extraction slurry is filtered and pH-adjusted if necessary. The solvent is then partially evaporated, or completely evaporated with water added back, to form a concentrated slurry. The concentrated slurry is then standardized to provide a known concentration of the psychoactive alkaloids that have been extracted. The standardized slurry may then be dried to result in a powdered psilocybin mushroom extract with a precisely defined purity.

Abstract: This invention relates to the extraction of psychoactive compounds from organisms for use in medicine. Extraction is carried out with a strong acid or strong base to either promote or inhibit dephosphorylation. The extract in the slurry form is standardized with added excipient so that when it is dried the powdered composition has a specified total psychoactive alkaloid concentration, with a known ratio of phosphorylated to dephosphorylated psychoactive alkaloids.

Abstract: The liquid composition includes a psychoactive alkaloid extract or synthetic psychoactive alkaloid. The alkaloids in the extract are predominantly dephosphorylated rather than phosphorylated. The injectable psychoactive alkaloid composition includes a carrier, an optional tonicity modifier, an optional antioxidant or preservative, an optional pH modifier, and optional further excipients. A process for obtaining an injectable psychoactive alkaloid composition includes dephosphorylating the alkaloid during extraction, purifying the extracted alkaloid, and standardizing it to a specific concentration by adding measured quantities of excipients.